Stockreport

Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF atopic dermatitis and BREADTH in eosinophilic asthma) with enrollment expected to finish for AD by end-2026 and top-line AD data targeted mid-2027, after phase I/IB show [Read more]